样式: 排序: IF: - GO 导出 标记为已读
-
The metabolism of melanin synthesis—From melanocytes to melanoma Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-03-06 Marelize Snyman, Rachel Elizabeth Walsdorf, Sophia Nicole Wix, Jennifer Gibson Gill
-
Topical antibiotics limit depigmentation in a mouse model of vitiligo Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-03-05 Ahmed Ahmed Touni, Rachel Sohn, Cormac Cosgrove, Rohan S. Shivde, Emilia R. Dellacecca, Rasha T. A. Abdel‐Aziz, Kettil Cedercreutz, Stefan J. Green, Hossam Abdel‐Wahab, I. Caroline Le Poole
-
Genetic insights into Tietz albinism‐deafness syndrome: A new dominant‐negative mutation in MITF Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-03-05 Kohei Yamamoto, Ken Okamura, Kazumasa Wakamatsu, Shosuke Ito, Kozue Akabane, Yosuke Arai, Junnosuke Kawaguchi, Yutaka Hozumi, Tamio Suzuki
-
Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-02-27 Xiao‐lian Liu, Zhou Run‐hua, Jing‐xuan Pan, Zhi‐jie Li, Le Yu, Yi‐lei Li
-
The Yucatan miniature swine as a model for post-inflammatory hyperpigmentation Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-02-16 Ying Wang, Emilee Herringshaw, R. Rox Anderson, Joshua Tam
-
Review: Are moles senescent? Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-02-15 Dorothy C. Bennett
-
Vitiligo non-responding lesions to narrow band UVB have intriguing cellular and molecular abnormalities that may prevent epidermal repigmentation Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-02-11 Nathaniel B. Goldstein, Andrea Steel, Landon Tomb, Zachary Berk, Junxiao Hu, Velmurugan Balaya, Laura Hoaglin, Kavya Ganuthula, Meet Patel, Erica Mbika, William A. Robinson, Dennis R. Roop, David A. Norris, Stanca A. Birlea
-
Molecular skin fluorescence imaging: A tool for evaluating early melanoma development Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2024-01-04 Amit Shachaf, Kevin Manbeck, Guang Yang, Catherine Shachaf
-
Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-12-29 Ling Deng, Hai-Yun Wang, Chun-Fang Hu, Xiao-Yun Liu, Kuntai Jiang, Juan-Juan Yong, Xiao-Yan Wu, Kai-Hua Guo, Fang Wang
-
Small extracellular vesicle-based human melanocyte and melanoma signature Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-12-29 Andrea Agüera-Lorente, Ainhoa Alonso-Pardavila, María Larrinaga, María Dolores Boyano, Esperanza González, Juan Manuel Falcón-Pérez, Aintzane Asumendi, Aintzane Apraiz
-
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-12-29 Viktoria Rydén, Ali Inan El-Naggar, Anthoula Koliadi, Cecilia Olsson Ladjevardi, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag
-
Clinical, histological, and molecular differences in melanoma due to different TERT promoter mutations subtypes. A retrospective cross-sectional study in 684 melanoma patients Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-12-28 Esperanza Manrique-Silva, Millán-Esteban David, Aguerralde-Martin Maider, Zaida García-Casado, Ruggero Moro, Celia Requena, Victor Través, Amaya Virós, Rajiv Kumar, Eduardo Nagore
Differences in survival according to the pTERT mutation subtypes (−124C > T, −146C > T, and tandem −138_139CC > TT) have been observed. The present study aimed to describe the clinical as the histopathological and molecular cutaneous melanoma features according to the presence of the three most prevalent pTERT mutation subtypes (−124C > T, −146C > T, and tandem −138_139CC > TT). A retrospective cross-sectional
-
Overview of current melanoma therapies Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-12-08 Anna Fateeva, Kevinn Eddy, Suzie Chen
-
Risk factors for sentinel lymph node metastasis in Korean acral and non-acral melanoma patients Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-11-27 Jee Yong Song, Young Jae Ryu, Ho Kyun Lee, Dong Hoon Lee, Yoo Duk Choi, Hyun Jeong Shim, Sook Jung Yun
-
Myron Gordon Award Lecture 2023: Painting the neural crest: How studying pigment cells illuminates neural crest cell biology Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-11-27 Robert N. Kelsh
-
MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14 Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-11-20 Gege Li, Changlong Zhou, Lu Wang, Yalong Zheng, Bo Zhou, Guoyan Li, Zhongyu Ma, Peng Sun, Yuantao Deng, Li Su, Junling Wang, Hongmei Cui
-
CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-11-17 Luka de Vos-Hillebrand, Simon Fietz, Philip Hillebrand, Zsófi Kulcsár, Marie Yatou Diop, Sarah Hollick, Alexander Philippe Maas, Sebastian Strieth, Jennifer Landsberg, Dimo Dietrich
-
Single-cell profiling of MC1R-inhibited melanocytes Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-11-16 H. Matthew Berns, Dawn E. Watkins-Chow, Sizhu Lu, Pakavarin Louphrasitthiphol, Tongwu Zhang, Kevin M. Brown, Pedro Moura-Alves, Colin R. Goding, William J. Pavan
-
TFE3 promotes ferroptosis in melanoma Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-11-12 Diogo Dias, Pakavarin Louphrasitthiphol, Colin R. Goding
-
Cytoglobin functions as a redox regulator of melanogenesis in normal epidermal melanocytes Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-11-02 Yo Tanaka, Misako Sato-Matsubara, Daisuke Tsuruta, Hiroshi Tanaka, Chiho Kadono, Koji Sugawara, Norifumi Kawada, Kazumasa Wakamatsu, Shosuke Ito, Katsutoshi Yoshizato
-
20th Anniversary of the Society for Melanoma Research: Celebrating two decades of progress in melanoma research Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-30 Ravi Amaravadi, Andrew Aplin, Meenhard Herlyn, Sheri Holmen, Richard White, Jessie Villanueva
Dear Colleagues, It is with great enthusiasm that we look forward to welcoming you to Philadelphia to celebrate a milestone for the melanoma research community: the 20th Anniversary of the Society for Melanoma Research (SMR). The SMR was established in 2003 during the First International Melanoma Research Congress in Philadelphia. Meenhard Herlyn and Kate O'Neill were the driving force behind the inaugural
-
Epilogue Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-30 Vijayasaradhi Setaluri, Evan P. and Marion Helfaer
It has been an honor and privilege to serve as Editor-in-Chief of Pigment Cell & Melanoma Research. This is a unique journal in many respects. It is the official journal of two scientific societies. Established first as Pigment Cell Research under the auspices of the Federation of Pigment Cell Societies, later became Pigment Cell & Melanoma Research by welcoming Society for Melanoma Research to be
-
List of reviewers for PCMR (01.01.2023–30.09.2023) Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-30
Abdallah, Marwa Abdel-Malek, Zalfa Abdelghani, Rania Abdelhak, Sonia Adams, David Agaimy, Abbas Akiyama, Toyoko Akkooi, Alexander C. J. van Albers, Eva-Maria Amu, Sylvie Andre, Catherine Aplin, Andrew Aplin, Andrew E. Arveiler, Benoît Asadi, Malek Hossein Ascierto, Paolo Aspelagh, Sandrine Atkins, Michael Attwa, Enayat Bae, Jung Min Bae, Yoon-Soo Cindy Bahrami, Armita Balak, Deepak Baqai, Waqas Saeed
-
Clinicopathological features, current status, and progress of primary central nervous system melanoma diagnosis and treatment Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-27 Pengna Guo, Xiaoting Wei, Zhen Guo, Di Wu
-
The MFSD12 p.Tyr182His common variant is sufficient to alter mouse agouti coat color Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-24 Dawn E. Watkins-Chow, Arturo A. Incao, Cecelia Rivas, Gene Elliott, Lisa J. Garrett, William J. Pavan
-
Next-generation of melanoma researchers: Trainee perspectives from around the world Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-11 Marie R. Webster, Roderick Brathwaite, Jeremy A. Bravo Narula, Vissy M. Elad, Yanni Ma, Mei Fong Ng, Manoel Oliveira de Moraes Junior, Majahonkhe Shabangu, Christina Tsiavou, Jessie Villanueva, Vito W. Rebecca
The Society for Melanoma Research (SMR) was created 20 years ago and has unequivocally contributed to the vast progress of the field, particularly for the treatment of melanoma patients with metastatic disease by facilitating synergistic collaborations between clinicians, researchers at the bench, and industry. In commemoration of the 20th anniversary of the first SMR International Congress (held in
-
Progress in melanoma treatment: Patient's perspectives Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-11 Gretchen M. Alicea, Jessie Villanueva, Marie R. Webster, Vito W. Rebecca
Upon the 20th Anniversary of the Society for Melanoma Research, we highlight the perspectives of patients aiming to help improve future experiences, outcomes, and their quality of life over the next 20 years. Five melanoma patients generously shared their inspiring and enlightening stories of diagnosis, treatment, and outcomes. Many patients had excellent medical teams that synergistically worked together
-
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA) Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-10-07 Alexander Z. Wei, Lanyi N. Chen, Marlana Orloff, Charlotte E. Ariyan, Maryam Asgari, Christopher A. Barker, Elizabeth Buchbinder, Sunandana Chandra, Kasey Couts, Michael M. Frumovitz, Andrew Futreal, Jeffrey E. Gershenwald, Ehab Y. Hanna, Benjamin Izar, Amy K. LeBlanc, Mario M. Leitao, Evan J. Lipson, David Liu, Martin McCarter, Jennifer L. McQuade, Yana Najjar, Suthee Rapisuwon, Sara Selig, Alexander
-
Nrf2 protein in melanoma progression, as a new means of treatment Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-09-30 Qun Feng, Xiaolin Xu, Shoulin Zhang
-
Laser capture microdissection provides a novel molecular profile of human primary cutaneous melanoma Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-09-30 Kristina Navrazhina, Sandra Garcet, Samuel C. Williams, Nicholas Gulati, Felix Kiecker, John W. Frew, Hiroshi Mitsui, James G. Krueger
-
A twenty year perspective on melanoma therapy Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-09-28 Keith T. Flaherty
-
A meta-analysis of the placebo response in vitiligo: Causes and consequences for the interpretation of clinical trials Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-09-27 Reinhart Speeckaert, Marijn M. Speeckaert, Nanja van Geel
-
Anti-melanogenic effect of exosomes derived from human dermal fibroblasts (BJ-5ta-Ex) in C57BL/6 mice and B16F10 melanoma cells Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-09-27 Jung Min Lee, Jung Ok Lee, Yujin Kim, You Na Jang, A. Yeon Park, Su-Young Kim, Hye Sung Han, Beom Joon Kim, Kwang Ho Yoo
Exosomes are involved in intercellular communication by transferring cargo between cells and altering the specific functions of the target cells. Recent studies have demonstrated the therapeutic effects of exosomes in several skin diseases. However, understanding of the effects of exosomes on anti-pigmentation is limited. Therefore, we investigated whether BJ-5ta exosomes (BJ-5ta-Ex) derived from human
-
Brief history of the Society for Melanoma Research: A community of clinicians, researchers, and friends Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-09-27 Vito W. Rebecca, Jessie Villanueva, Marie R. Webster
-
Twenty years of research in melanoma therapy–From “nothing works” to cures: A personal account Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-09-19 Meenhard Herlyn, Jessie Villanueva
1 THE EARLY YEARS In the late 1990s and early 2000s the mood in the melanoma field was grim. “Nothing works,” said our oncology colleague Lynn Schuchter, after the third large Phase III trial in immune therapy (a MAGE3 trial) failed. Don Morton's Bacillus Calmette-Guérin (BCG) trial had also just failed, and he was truly disappointed (Eilber et al., 1976; Morton et al., 1974). There were no alternatives
-
Unsuspected consequences of synonymous and missense variants in OCA2 can be detected in blood cell RNA samples of patients with albinism Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-31 Vincent Michaud, Angèle Sequeira, Elina Mercier, Eulalie Lasseaux, Claudio Plaisant, Smail Hadj-Rabia, Sandra Whalen, Dominique Bonneau, Anne Dieux-Coeslier, Fanny Morice-Picard, Juliette Coursimault, Benoît Arveiler, Sophie Javerzat
Oculocutaneous albinism type 2 (OCA2) is the second most frequent form of albinism and represents about 30% of OCA worldwide. As with all types of OCA, patients present with hypopigmentation of hair and skin, as well as severe visual abnormalities. We focused on a subgroup of 29 patients for whom genetic diagnosis was pending because at least one of their identified variants in or around exon 10 of
-
MITF E318K: A rare homozygous case with multiple primary melanoma Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-27 Courtney K. Wallingford, Ellie J. Maas, Antonia Howard, Emily DeBortoli, Deboshmita Bhanja, Katie Lee, Adam Mothershaw, Kasturee Jagirdar, Rod Willett, Brigid Betz-Stablein, Richard A. Sturm, H. Peter Soyer, Aideen M. McInerney-Leo
-
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-25 Inna Smalley, Adrienne Boire, Priscilla Brastianos, Harriet M. Kluger, Eva Hernando-Monge, Peter A. Forsyth, Kamran A. Ahmed, Keiran S. M. Smalley, Sherise Ferguson, Michael A. Davies, Isabella C. Glitza Oliva
-
Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-23 Zhen Zeng, Hung Long Ngo, Martina Proctor, Helen Rizos, Riccardo Dolcetti, Jazmina Gonzalez Cruz, James W. Wells, Brian Gabrielli
-
Activated Akt expression is associated with the recurrence of primary melanomas and further refines the prognostic and predictive values for relapse in acral melanomas Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-18 Kohei Nojima, Masahiro Hayashi, Atsushi Tanemura, Hind Al-Busani, Toru Saito, Tamio Suzuki, Masashi Ishikawa, Taisuke Mori, Shogo Wada, Naoya Yamazaki, Ichiro Katayama, Hiroki Mori, Hiroo Yokozeki, Naoko Okiyama, Yoshiyuki Sasaki, Takeshi Namiki
A PTEN deficiency leads to the activation of phospho-Akt at serine 473 (p-Akt) and promotes the tumorigenesis of melanomas by coupling with NUAK2 amplification. We tested the prognostic impact of p-Akt and/or NUAK2 expression on the relapse-free survival (RFS) and overall survival (OS) of melanoma patients. Primary tumors from patients with acral melanomas (112), Low-cumulative sun damage (CSD) melanomas
-
Melanoma literacy among the general population of three western US states Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-13 Sancy A. Leachman, Emile Latour, Brian Detweiler-Bedell, Jerusha B. Detweiler-Bedell, Adrienne Zell, Elizabeth Wenzel, Elizabeth Stoos, Jacob H. Nelson, Jack Wiedrick, Elizabeth G. Berry, Jane Lange, Ruth Etzioni, Jodi A. Lapidus
-
Modeling of pigmentation disorders associated with MITF mutation in Waardenburg syndrome revealed an impaired melanogenesis pathway in iPS-derived melanocytes Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-09 Jie Wen, Jian Song, Jiale Chen, Zhili Feng, Qiancheng Jing, Wei Gong, Xiaoming Kang, Lingyun Mei, Chufeng He, Lu Ma, Yong Feng
-
Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-08 J. S. W. Borgers, F. H. Burgers, A. Schina, O. J. Van Not, A. J. M. van den Eertwegh, C. U. Blank, M. J. B. Aarts, F. W. P. J. van den Berkmortel, J. W. B. de Groot, G. A. P. Hospers, E. Kapiteijn, D. Piersma, R. S. van Rijn, A. M. Stevense-den Boer, A. A. M. van der Veldt, G. Vreugdenhil, M. J. Boers-Sonderen, M. W. J. M. Wouters, K. P. M. Suijkerbuijk, J. V. van Thienen, J. B. A. G. Haanen
Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that the exposome, an accumulation of host-extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild-type melanoma
-
Optimisation of skin phototype classification Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-08-07 Sophie S. Lim, Tasneem F. Mohammad, Indermeet Kohli, Iltefat Hamzavi, Michelle Rodrigues
-
Melanoma in infants, caused by a gene fusion involving the anaplastic lymphoma kinase (ALK) Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-07-20 Ifeoma U. Perkins, Serena Y. Tan, Timothy H. McCalmont, Pauline M. Chou, Thaddeus W. Mully, Pedram Gerami, Jason H. Pomerantz, Miguel Reyes-Múgica, Daniel M. Balkin, Lacey L. Kruse, Benjamin Huang, Jennifer L. Reichek, Noopur Gangopadhyay, Simon Chiosea, Jared R. Green, Sarah L. Chamlin, Ilona J. Frieden, Boris C. Bastian, Iwei Yeh
-
Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-07-20 Valentin Aebischer, Amar Abu-Ghazaleh, Gisela Metzler, Lena Riedl, Claus Garbe, Lukas Flatz, Thomas Eigentler, Stephan Forchhammer
-
Survival benefit of sentinel lymph node biopsy in Asian melanoma patients Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-07-19 Che-Chia Hsu, Yi-Hua Liao, Yi-Shuan Sheen
-
Dynamic regulation of chromatin accessibility during melanocyte stem cell activation Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-07-18 Seoyeon Lee, Luye An, Paul D. Soloway, Andrew C. White
-
Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-07-07 Vincent Pozorski, Yeonhee Park, Yusuf Mohamoud, Dahlia Tesfamichael, Hamid Emamekhoo, Alexander Birbrair, Mark R. Albertini, Vincent T. Ma
-
Identification and characterization of the compound heterozygous variants of TYR gene in a northern Chinese family with Oculocutaneous albinism type 1 Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-07-05 Shuhan Si, Xueyuan Jia, Lidan Xu, Qian Qin, Jie Wu, Wei Ji, Kexian Dong, Xuelong Zhang, Lin Cao, Hao Wang, Peng Liu, Rongrong Wang, Jing Bai, Songbin Fu, Yun Huang, Wenjing Sun
Oculocutaneous albinism (OCA) is a genetically heterogeneous disease and is most inherited in an autosomal recessive manner. The characteristic manifestation of OCA is due to disfunction of melanin synthesis. OCA1 is the most severe subtype of OCA and is caused by homozygous or compound heterozygous variants in tyrosinase (TYR) gene, which is the key gene for melanin synthesis. This study aimed to
-
Unveiling the mystery of Riehl's melanosis: An update from pathogenesis, diagnosis to treatment Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-07-04 Yuecen Ding, Zhongyi Xu, Leihong Flora Xiang, Chengfeng Zhang
-
Prognostic biomarkers for survival in mucosal melanoma Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-06-30 Julia C. Thierauf, Stefan T. Kaluziak, Elizabeth Codd, Stacy N. Dybel, Soma Jobbagy, Rashi Purohit, Alex A. Farahani, Aikaterini Dedeilia, Vivek Naranbhai, Mai P. Hoang, Adam S. Fisch, Lauren Ritterhouse, Genevieve M. Boland, Jochen K. Lennerz, A. John Iafrate
Mucosal melanoma (MM) is a rare subtype of melanoma with an aggressive clinical course. In cutaneous melanoma (CM), the absence of pigmentation and presence of NRAS/KRAS mutations are biomarkers indicating an aggressive clinical course with shorter overall survival. Similar data for MM are missing. We present the real-world outcome data in a cohort of genotyped MM patients and assessed the prognostic
-
The OSUMMER lines: A series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6 Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-06-21 Brandon M. Murphy, Daelin M. Jensen, Tiffany E. Arnold, Renan Aguilar-Valenzuela, Jase Hughes, Valentina Posada, Kimberly T. Nguyen, Vi T. Chu, Kenneth Y. Tsai, Craig J. Burd, Christin E. Burd
-
Melanoma and subcutaneous adipose tissue: Role of peritumoral adipokines in disease characterization and prognosis Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-06-19 Elisa Molinelli, Gabriele Ceccarelli, Sonia Fantone, Eleonora Di Mercurio, Daisy Gambini, Andrea Maurizi, Jessica Perugini, Giovanni Tossetta, Valerio Brisigotti, Edoardo De Simoni, Claudia Sapigni, Giulio Rizzetto, Anna Campanati, Oriana Simonetti, Daniela Marzioni, Annamaria Offidani
In the last decades, the concept of adipose organ has emerged, giving adipose tissue an active endocrine and immunologic function through the secretion of multiple cytokines and chemokines that seem to be implicated in the development and progression of several cancer, including cutaneous melanoma. In this pilot experimental study, we analyzed the expression in the peritumor subcutaneous adipose tissue
-
Revisiting the role of varicella zoster virus in segmental vitiligo. Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-06-15 Rhea Ahuja,Shivangi Garg,Somesh Gupta
-
Trained immunity in the pathogenesis of vitiligo Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-06-09 Nicoline F. Post, Greta Ginski, Rens Peters, Nathalie O. P. Van Uden, Marcel W. Bekkenk, Albert Wolkerstorfer, Mihai G. Netea, Rosalie M. Luiten
Vitiligo is caused by an autoimmune reaction against melanocytes leading to melanocyte loss. The cause of vitiligo is an interaction between genetic susceptibility and environmental factors. Both the adaptive immune system—through cytotoxic CD8+ T cells and melanocyte specific antibodies—and the innate immune system are involved in these immune processes in vitiligo. While recent data stressed the
-
Uric acid is a major chemical constituent for the whitish coloration in the medaka leucophores Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-05-30 Makoto Goda, Asuka Miyagi, Takuya Kitamoto, Minako Kondo, Hisashi Hashimoto
In whitish parts of teleost skin, the coloration is attributed to a light scattering phenomenon within light-reflecting chromatophores, namely leucophores and iridophores, which contain high refractive index materials in their cytoplasmic organelles, leucosomes and light-reflecting platelets, respectively. Previous chemical examinations revealed that guanine is a major constituent of the materials
-
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-05-27 Sebastian Ochenduszko, Javier García Sanchez, María José Juan Fita, Inés González-Barrallo, Julio Herrero Colomina, Karmele Mujika, Roberto Diaz Beveridge, Silverio Ros Martínez, Blanca Sánchez Lafuente, Alberto Cunquero Tomas, Alfonso Berrocal Jaime, Pablo Cerezuela Fuentes, Pablo Luna Fra, Alicia Gervás Peeters, José Andrés Meana García, María Asunción Algarra García, Javier Perez Altozano, Maria
Anti-programmed death-1 (anti-PD1) treatment has significantly improved outcomes of advanced melanoma with a considerable percentage of patients achieving complete response (CR). This real-world study analyzed the feasibility of elective anti-PD1 discontinuation in advanced melanoma patients with CR and evaluated factors related to sustained response. Thirty-five patients with advanced cutaneous or
-
Increased anti-oxidative action compensates for collagen tissue degeneration in vitiligo dermis Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-05-25 Kazunori Yokoi, Yoshiaki Yasumizu, Naganari Ohkura, Koei Shinzawa, Daisuke Okuzaki, Nene Shimoda, Hideya Ando, Nanako Yamada, Manabu Fujimoto, Atsushi Tanemura
Vitiligo is a common depigmentation disorder characterized by the selective loss of melanocytes. In our daily clinic experience, we noticed that the skin tightness of hypopigmented lesions would be more evident in comparison to that of uninvolved perilesional skin in vitiligo patients. Therefore, we hypothesized that collagen homeostasis might be maintained in vitiligo lesions, irrespective of the
-
BMI1 is required for melanocyte stem cell maintenance and hair pigmentation Pigment Cell Melanoma Res. (IF 4.3) Pub Date : 2023-05-03 Molly M. Wilson, Paul S. Danielian, Griffin Salus, Roberta Ferretti, Charles A. Whittaker, Jacqueline A. Lees
The epigenetic repressor BMI1 plays an integral role in promoting the self-renewal and proliferation of many adult stem cell populations, and also tumor types, primarily through silencing the Cdkn2a locus, which encodes the tumor suppressors p16Ink4a and p19Arf. However, in cutaneous melanoma, BMI1 drives epithelial-mesenchymal transition programs, and thus metastasis, while having little impact on